Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Demonstrate Lot-to-lot Consistency of Final Production Method of GSK Biologicals' Hib-MenAC Vaccine Mixed Extemporaneously With Tritanrix™-HepB & Demonstrate Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Healthy Infants at 2, 4 and 6 Months

NCT00197275 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00197275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00197275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Demonstrate Lot-to-lot Consistency of Final Production Method of GSK Biologicals' Hib-MenAC Vaccine Mixed Extemporaneously With Tritanrix™-HepB & Demonstrate Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Healthy Infants at 2, 4 and 6 Months
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
November 30, 2006
Enrollment
800
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, hepatitis b, tetanus, whole cell pertussis